<p>每个工作日，CNBC 投资俱乐部与吉姆·克莱默（Jim Cramer）一起发布《收官时刻》——一份可操作的下午更新，正好赶上华尔街最后一个小时的交易。周四，股票在半导体和与人工智能相关的公司带动下上涨。台积电在报告强劲的第四季度业绩并预测资本支出增加后，股价上涨超过 5%。台积电的强劲表现推动了芯片板块：俱乐部成员英伟达（Nvidia）和美光（Micron）各上涨 3%，而投资组合持股博通（Broadcom）上涨 1.5%。金融股也获得了提振。高盛（Goldman Sachs）在第四季度业绩超出预期后上涨 5%，尽管由于苹果卡转移到摩根大通（JPMorgan）的一次性影响，收入略显不足。俱乐部成员贝莱德（BlackRock）在第四季度业绩超出预期后飙升 6%，突显出基础费用的强劲增长。根据标准普尔短期振荡器（S &amp; P Short Range Oscillator），市场在周四进入了超买区域，我们通过削减多佛（Dover）持仓来提高现金比例。由于路透社报道美国食品药品监督管理局（FDA）延长了对几种药物的审查截止日期，包括礼来（Eli Lilly）的实验性每日一次 GLP-1 药丸 orforglipron，用于治疗 2 型糖尿病和肥胖，礼来的股价下跌了 5%。GLP-1 市场一直由注射剂驱动，但由于患者对药丸的偏好，肥胖药物类别预计将加速增长。orforglipron 的 FDA 批准可能成为俱乐部股票礼来的主要催化剂，特别是在竞争对手诺和诺德（Novo Nordisk）成为首个获得 GLP-1 减肥药 FDA 批准的公司后。我们继续认为礼来的批准是 “何时，而不是是否”，特别是因为 orforglipron 相较于诺和的药丸具有更大的优势，可能更受患者欢迎。该药的目标批准日期为 4 月 10 日，礼来发言人确认根据当前 FDA 的指导，批准可能在第二季度到来。礼来的股票也受到更广泛的医疗保健行业波动的影响，因为特朗普政府寻求调整药物和保险公司的定价。华尔街再次对好市多（Costco）表示热情。伯恩斯坦（Bernstein）在给投资者的报告中称该零售商为 “终极复合增长者”，因为其能够以稳定的速度增长收益和自由现金流。分析师们还认为好市多的股票被低估，引用了长期以来每股收益和股本回报的持续增长。该公司认为，未来的增长证明了好市多的市盈率在 45 到 50 倍之间是合理的。由于对其高估值、会员续费率下降和购物趋势放缓的担忧，好市多在去年几乎下跌了 6%，成为不受欢迎的零售商。这也是我们在 12 月 16 日将好市多的持仓减半的原因，锁定了 2020 年初购买股票时的 200% 收益。但在好市多本月早些时候发布强于预期的 12 月销售数据后，负面情绪转为积极。吉姆·克莱默表示，在股票已经上涨 10% 开始新年后，好市多并未停止上涨。伯恩斯坦也认为，尽管过去六个月该股下跌了 1.5%，但仍有进一步上涨的空间。接下来：收盘后没有重大财报。银行财报将在周五继续，PNC 金融将在开盘前发布报告。周五的经济日历也较为清淡，将发布美联储的 12 月工业生产数据和全国住房建筑商协会的 1 月住房指数。（请查看此处获取吉姆·克莱默慈善信托中的股票完整列表。）作为 CNBC 投资俱乐部的订阅者，您将在吉姆进行交易之前收到交易提醒。吉姆在发送交易提醒后等待 45 分钟才会买入或卖出他慈善信托投资组合中的股票。如果吉姆在 CNBC 电视上谈论过某只股票，他将在发出交易提醒后等待 72 小时再执行交易。上述投资俱乐部信息受我们的条款和条件以及隐私政策的约束，并附有免责声明。您收到的与投资俱乐部相关的任何信息并不构成任何受托义务或责任。没有任何特定的结果或利润是有保证的。</p>

礼来

开市客

<p>礼来的股票在 FDA 延长其糖尿病药物 orforglipron 的审查截止日期后下跌了 5%。尽管面临这一挫折，分析师们认为 FDA 在 4 月 10 日之前批准的可能性很大，这可能成为股票的重要催化剂。与此同时，开市客在 12 月销售强劲后获得了积极的市场情绪，Bernstein 称其被低估，并预测进一步增长。市场也受到半导体股票和金融股强劲表现的提振，摩根士丹利和黑石集团报告的收益超出预期。总体而言，市场仍处于超买区域，促使一些投资者削减持仓</p>

<p>Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks were climbing on Thursday led by semiconductors and AI-related names. Taiwan Semiconductor rallied more than 5% after reporting strong fourth quarter results and forecasting higher captial spending. That strength in TSMC was lifting the chip group: Club name Nvidia and Micron were each up 3%, and portfolio holding Broadcom was up 1.5%. Financials were also getting a boost. Goldman Sachs rose 5% after beating fourth quarter earnings, though revenue came in light due to a one-time impact from the transfer of Apple Card to JPMorgan . Fellow Club name BlackRock surged 6% on its fourth quarter beat, highlighting strong base fee growth. The market entered Thursday in overbought territory, according to the S &amp; P Short Range Oscillator , and we raised cash into strength by trimming our Dover position. Eli Lilly shares dropped 5% on a Reuters report that the Federal Drug Administration extended review deadlines on several drugs, including Lilly's orforglipron — its experimental, once-daily GLP-1 pill to treat type two diabetes and obesity. The GLP-1 market has been driven by injectables, but the obesity pill category is expected to accelerate the category, given patients' preference for pills. FDA approval of orforglipron would likely be a major catalyst for Club stock Eli Lilly , especially after rival Novo Nordisk jumped on becoming the first to secure FDA approval for a GLP-1 weight-loss pill. We continue to view approval for Lilly as a &#34;when, not if,&#34; particularly because orforglipron has advantages over Novo's pill that could make it more appealing to patients. The drug has a target approval date of April 10, and a Lilly spokesperson confirmed approval could land in the second quarter, based on current FDA guidance. Lilly's stock was also feeling the weight of broader health care sector volatility as the Trump administration seeks to adjust pricing for drugs and insurance companies. Wall Street is warming up to Costco again. Bernstein called the retailer the &#34;ultimate compounder&#34; for its ability to grow earnings and free cash flow at a steady rate in a note to investors. Analysts also think Costco shares are undervalued, citing consistent earnings per share growth and return on equity over the long term. The firm argues the growth that lies ahead justifies Costco's price-to-earnings multiple of 45 to 50 times. Costco had been an out-of-favor retailer after losing nearly 6% last year on concerns about its elevated valuation, slipping membership renewal rates, and slower shopping trends. It's what made us cut our Costco position in half on Dec. 16, booking a 200% gain on shares purchased in early 2020. But negative sentiment turned positive after Costco delivered stronger-than-expected December sales earlier this month. Jim Cramer has said that Costco is not done going higher after the stock has already gained 10% to start the year. Bernstein also sees further upside from here with the stock still down 1.5% over the past six months. Up next: There are no major earnings reports after the closing bell. Bank earnings continue Friday, with PNC Financial scheduled to report before the open. The economic calendar is also light Friday, with the release of December industrial production data from the Federal Reserve and the January housing index from the National Association of Home Builders. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.</p>
<div class="lb-trans"><p>每个工作日，CNBC 投资俱乐部与吉姆·克莱默（Jim Cramer）一起发布《收官时刻》——一份可操作的下午更新，正好赶上华尔街最后一个小时的交易。周四，股票在半导体和与人工智能相关的公司带动下上涨。台积电在报告强劲的第四季度业绩并预测资本支出增加后，股价上涨超过 5%。台积电的强劲表现推动了芯片板块：俱乐部成员英伟达（Nvidia）和美光（Micron）各上涨 3%，而投资组合持股博通（Broadcom）上涨 1.5%。金融股也获得了提振。高盛（Goldman Sachs）在第四季度业绩超出预期后上涨 5%，尽管由于苹果卡转移到摩根大通（JPMorgan）的一次性影响，收入略显不足。俱乐部成员贝莱德（BlackRock）在第四季度业绩超出预期后飙升 6%，突显出基础费用的强劲增长。根据标准普尔短期振荡器（S &amp; P Short Range Oscillator），市场在周四进入了超买区域，我们通过削减多佛（Dover）持仓来提高现金比例。由于路透社报道美国食品药品监督管理局（FDA）延长了对几种药物的审查截止日期，包括礼来（Eli Lilly）的实验性每日一次 GLP-1 药丸 orforglipron，用于治疗 2 型糖尿病和肥胖，礼来的股价下跌了 5%。GLP-1 市场一直由注射剂驱动，但由于患者对药丸的偏好，肥胖药物类别预计将加速增长。orforglipron 的 FDA 批准可能成为俱乐部股票礼来的主要催化剂，特别是在竞争对手诺和诺德（Novo Nordisk）成为首个获得 GLP-1 减肥药 FDA 批准的公司后。我们继续认为礼来的批准是 “何时，而不是是否”，特别是因为 orforglipron 相较于诺和的药丸具有更大的优势，可能更受患者欢迎。该药的目标批准日期为 4 月 10 日，礼来发言人确认根据当前 FDA 的指导，批准可能在第二季度到来。礼来的股票也受到更广泛的医疗保健行业波动的影响，因为特朗普政府寻求调整药物和保险公司的定价。华尔街再次对好市多（Costco）表示热情。伯恩斯坦（Bernstein）在给投资者的报告中称该零售商为 “终极复合增长者”，因为其能够以稳定的速度增长收益和自由现金流。分析师们还认为好市多的股票被低估，引用了长期以来每股收益和股本回报的持续增长。该公司认为，未来的增长证明了好市多的市盈率在 45 到 50 倍之间是合理的。由于对其高估值、会员续费率下降和购物趋势放缓的担忧，好市多在去年几乎下跌了 6%，成为不受欢迎的零售商。这也是我们在 12 月 16 日将好市多的持仓减半的原因，锁定了 2020 年初购买股票时的 200% 收益。但在好市多本月早些时候发布强于预期的 12 月销售数据后，负面情绪转为积极。吉姆·克莱默表示，在股票已经上涨 10% 开始新年后，好市多并未停止上涨。伯恩斯坦也认为，尽管过去六个月该股下跌了 1.5%，但仍有进一步上涨的空间。接下来：收盘后没有重大财报。银行财报将在周五继续，PNC 金融将在开盘前发布报告。周五的经济日历也较为清淡，将发布美联储的 12 月工业生产数据和全国住房建筑商协会的 1 月住房指数。（请查看此处获取吉姆·克莱默慈善信托中的股票完整列表。）作为 CNBC 投资俱乐部的订阅者，您将在吉姆进行交易之前收到交易提醒。吉姆在发送交易提醒后等待 45 分钟才会买入或卖出他慈善信托投资组合中的股票。如果吉姆在 CNBC 电视上谈论过某只股票，他将在发出交易提醒后等待 72 小时再执行交易。上述投资俱乐部信息受我们的条款和条件以及隐私政策的约束，并附有免责声明。您收到的与投资俱乐部相关的任何信息并不构成任何受托义务或责任。没有任何特定的结果或利润是有保证的。</p>
</div>

这只制药股票刚刚遭受重创，但仍有一个重要的催化剂即将到来